Top Page
Trendlines Group
(SGX:42T)
Trendlines Group (42T) vs. iShares MSCI Singapore ETF (EWS)
Trendlines Group Business Overview & Revenue Model
Trendlines Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -8.32M | 1.72M | 4.50M | 3.58M | 2.30M | -3.76M |
| Gross Profit | -19.53M | -1.73M | -793.00K | -3.83M | -5.04M | -15.68M |
| EBITDA | -19.34M | -9.28M | -33.93M | -16.39M | 3.95M | -14.98M |
| Net Income | -18.87M | -9.43M | -33.99M | -14.48M | 6.56M | -4.93M |
Balance Sheet | ||||||
| Total Assets | 73.26M | 75.35M | 78.07M | 107.99M | 121.08M | 154.32M |
| Cash, Cash Equivalents and Short-Term Investments | 2.89M | 5.89M | 6.11M | 6.57M | 18.46M | 14.07M |
| Total Debt | 5.45M | 4.15M | 4.64M | 4.85M | 10.01M | 7.39M |
| Total Liabilities | 8.63M | 7.32M | 9.00M | 12.10M | 18.54M | 27.09M |
| Stockholders Equity | 65.47M | 68.55M | 70.89M | 96.99M | 103.09M | 127.21M |
Cash Flow | ||||||
| Free Cash Flow | -9.84M | -8.86M | -6.42M | -15.04M | 76.00K | -4.50M |
| Operating Cash Flow | -9.80M | -8.84M | -6.34M | -14.93M | 650.00K | -3.86M |
| Investing Cash Flow | -200.93K | -948.00K | 1.92M | 2.05M | -598.00K | -5.83M |
| Financing Cash Flow | 5.26M | 8.64M | 5.97M | 3.13M | 3.60M | -490.00K |
Trendlines Group Peers Comparison
Trendlines Group Corporate Events
Celleste-Bio, a portfolio company of Trendlines Group, has achieved a significant breakthrough by producing the first chocolate-grade cocoa butter using plant cell culture technology. This innovation is chemically and sensorially identical to conventional cocoa butter and offers a scalable, zero-waste production process. This development is particularly impactful given the current challenges in the global cocoa industry, including record-high prices and supply deficits due to climate-driven crop failures and disease outbreaks.
Trendlines Group Ltd. has announced several corporate updates following its Special General Meeting, including the completion of the first tranche of a Proposed Subscription and disclosures of interests by key stakeholders. Additionally, its portfolio companies have made significant strides, with SOLVEAT Ltd. entering a joint development agreement with a major beverage company and SEGER Surgical Solutions Ltd. gaining acceptance into the FDA’s Safer Technologies Program, potentially enhancing their market positioning.
Trendlines Group Ltd. has completed the first installment of its proposed subscription, issuing new ordinary shares to subscribers. The subscription process ensures that LH, a major subscriber, does not exceed a 29.77% stake in the company’s total enlarged issued and paid-up share capital. The newly issued shares are expected to be listed on the Catalist of the SGX-ST around 24 September 2025, aligning with the company’s strategic capital management and shareholder engagement initiatives.
Trendlines Group Ltd. has announced the receipt of a listing and quotation notice from the Singapore Exchange Securities Trading Limited (SGX-ST) for the proposed subscription of up to 208,629,396 new ordinary shares. This development marks a significant step in the company’s capital-raising efforts, potentially enhancing its market presence and operational capabilities. The company is required to place out the first installment of these shares within seven market days, and further updates will be provided to shareholders as necessary.
The Trendlines Group Ltd. held a Special General Meeting at the Suntec Singapore Convention & Exhibition Centre, with several directors attending in person and others via video conference. The meeting was chaired by Mr. Sin Boon Ann, who was appointed to lead the proceedings in place of Ms. Nehama Ronen. The meeting confirmed the presence of a quorum and proceeded with the agenda, which included the announcement of a circular dated 2 July 2025.
Trendlines Group Ltd. has announced several updates following its Special General Meeting and the release of its H1 2025 financial results. The company also completed a Rights Issue, issuing and listing new shares. In its portfolio, Colorcon Ventures invested in Phytolon Ltd. to enhance natural colorant technologies, while EcoPhage Ltd. submitted a biopesticide application to the US EPA, indicating progress in their respective fields. These developments highlight Trendlines’ active role in advancing innovative solutions and expanding its market influence.
Trendlines Group Ltd. announced the results of its non-renounceable, non-underwritten rights issue, which closed on August 15, 2025. The rights issue saw a subscription level of 124.99%, with valid acceptances and excess applications exceeding the available shares. This successful capital raise indicates strong investor confidence and is expected to bolster the company’s financial position, enabling further investments in its core sectors of medical and agricultural technology.
Trendlines Group Ltd. announced the grant of options to its External Directors, Non-Executive Directors, and CEO, Mr. Haim Brosh, as part of its 2015 Share Option Plan. This move, approved by shareholders, involves 42,750,000 options exercisable into ordinary shares, potentially impacting the company’s market position by aligning the interests of its leadership with shareholders and enhancing its governance framework.
Trendlines Group Ltd. has announced a series of corporate updates, including the scheduling of a Special General Meeting on 6 August 2025, following their Rights Issue announcement. The company is also preparing to release its financial results for the first half of the year by 14 August 2025. Additionally, PregnanTech Ltd., one of Trendlines’ portfolio companies, was featured in In Vivo magazine for its device aimed at preventing preterm births, highlighting the company’s ongoing impact in the medical technology sector.